Rixathon® (rituximab)

Rixathon® Approval Pending

Rixathon® (rituximab)

Rixathon® Approval Pending

U.S. License Holder:

Sandoz

Date of License:

aBLA accepted by FDA September-2017; Complete Response Letter May-2018

Last Update:

Dec-15-2024

approved_indications FDA-Approved Indications

RIXATHON (rituximab) is not FDA-approved. An aBLA has been accepted by the FDA.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Riximyo® (Sandoz) (April-2020)

Biosimilars Approved In The E.U.

Rixathon® (Sandoz) (June-2017)
Riximyo® (Sandoz) (June-2017)

Biosimilars Approved In Australia

Riximyo® (Sandoz) (November-2017)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2017-02036

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Sandoz, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-02042

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Sandoz, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-13507 (D.N.J.)

U.S. Patent Nos.
6,121,428 (Protein Recovery) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,489,447 (Protein Purification) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 6,870,034 (Protein Purification) 7,381,560 (Expression and Use of Anti-CD20 Antibodies) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,820,161 (Treatment of Autoimmune Diseases) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies) 8,314,225 (Heavy Chain Mutant Leading to Improved Immunoglobulin Production) 8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,545,843 (Treatment of Vasculitis) 8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,710,196 (Protein Purification) 8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody) 9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies) 9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media)

Plaintiffs
Biogen, Inc.; City of Hope; Genentech, Inc.

Defendants
Sandoz GmbH; Sandoz Inc.; Sandoz International GmbH

Status
Joint Stipulation of Dismissal

BPCIA
Y

Related News

Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
November 30, 2024
Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)
April Breyer Menon Corinne E. Atton Joyce L. Nadipuram Robert S. Schwartz, Ph.D.
November 30, 2024
Venable’s BiologicsHQ Monthly Injection – May 2018
April M. Breyer Menon Joseph K. Yarsky Corinne E. Atton Robert S. Schwartz, Ph.D.
June 8, 2018
Venable’s BiologicsHQ Monthly Injection – August/September 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 5, 2017

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha